Eric Luellen is an award-winning American technology innovator and entrepreneur with 20 years experience leading and growing technologies and companies, including enterprise platform and software development in AI, predictive analytics, bioinformatics, data mining, data warehousing, and custom application development in medicine, education, and telecommunications.

Mr. Luellen earned a Bachelor of Arts degree in liberal arts at American University, completed a fellowship in e-commerce at the Wharton School of Business and 10 certificates at Harvard Law School's Program on Negotiations (5), MIT (3), Columbia (1), and Caltech (1). Mr. Luellen studied environmental health, neurobiology, epidemiology, infectious disease, medical genomics, and virology at Harvard University. He holds a Master of Science degree in health informatics from Northwestern University where his thesis devised a new generalized method to predict health using ensemble machine learning of genomic visualizations.

Steve is a problem-solver taking ideas and problems and creating technology solutions that address the issues at hand. He has been involved in various aspects of computing for 21 years in numerous capacities. Evolving from a UNIX administrator, to firewall administrator, to security consultant and penetration tester, to SaaS entrepreneur. Steve has architected, deployed, evaluated, and maintained numerous infrastructures and technologies. His experience spans multiple industries including energy, healthcare, banking, and higher education. He has a love-hate relationship with technology that sees both the good and evil that it creates and often enjoys old-fashioned paper notes (much harder to hack into remotely). When not overseeing technology he can be found at a baseball game. He has been married for 20 years and has five children.

Steve holds a bachelor's degree in business administration with a concentration in information systems from Texas A&M University.

Jeffrey leads go-to-market and customer engagement activities, in addition to overseeing operational aspects of the business, including country-specific strategies, marketing and business development, and partner and client relationships. He has more than 20 years of international management experience, including enterprise software and SaaS services. Prior to joining Bioinformatix, Jeffrey served as Chief of International Government Affairs for a global technology security company.

Edward Cummings is an acknowledged leader in the business, technology and intellectual property of privacy, cybersecurity and data analytics. As Director of the Business Development and Strategy team for Microsoft’s $30B Platforms business, he was responsible for assessment of each of Microsoft’s security technology acquisitions during its major security pushes in 2000-2009, including acquisitions of antivirus, emulation, sandboxing/virtualization and network penetration technologies and creating Windows’ overall M&A strategy. He also played a direct role in Microsoft’s global response to the Blaster and Slammer malware attacks, and his team led the initial cybersecurity policy and standards engagements Microsoft developed with governments worldwide as Microsoft’s core technologies became central to global business and communications. Later he led the creation and rollout of Microsoft’s first preinstalled PC anti-malware consumer product, which was rolled out to PC manufacturers in 30 countries in a 12 month period.

From Microsoft Cummings moved to the Center for Commercialization of the University of Washington, leading the conversion of research technologies into commercial opportunities at one of the world’s leading computer science research institutions. Cummings oversaw commercialization of device security, encryption, data analytics and energy conservation developments as part of the UW’s computer science and electrical engineering portfolio. He now runs his own technology strategy consulting firm, providing technology and strategy consulting to Fortune 500 clients as well as to startups in the medical, consumer product and mobile application spaces.

Jürgen Homberg spent over a decade working in the financial sector both in Germany and in Mexico, mainly in the M&A area. In 2016 he joined Surrey Capital Partners as partner. He is also an expert in both, consumer products and chemicals, and has been CEO and Chairman of the Board at Grupo Holck since 2008.

Mr. Homberg is a German national based in Mexico, and is an expert in Latin America. He has a vast experience in international business. He is an expert negotiator and is known for finding unique solutions to complex problems by thinking outside the box.

Mr. Homberg earned a Bachelor’s degree in Business Administration and Finance from Trinity College, and an Mba from Edinburgh School of Business. He also earned a graduate level diploma in finance from CEMV, a graduate certificate in Strategig Management from Harvard University, and is currently in the Owner President Managment Program at Harvard Business School.

Amy Odom is a principal in Dentons' Public Policy and Regulation practice. Amy brings to Dentons more than 20 years of multi-state and federal governmental affairs advocacy, strategy and tactical grassroots experience, in both the private and public sectors.

Amy offers clients a knowledgeable and broad perspective of the impact and implications that federal and state legislative and regulatory policy can have on their overall business priorities, and is adept at helping clients understand how to strategically win in a complex political environment by helping them create successful public affairs campaigns geared at achieving their goals.

Prior to joining Dentons, Amy was the Vice President for State Affairs for Anthem (formerly WellPoint), the largest health benefits company in the United States, and was responsible for all aspects of Anthem’s advocacy efforts in its fourteen commercial footprint states. Prior to assuming that position, Amy was the Vice President of Anthem’s federal affairs office in Washington, DC, and was responsible for the company's political and advocacy strategy during the health care reform debate.

Amy began her career as the principal assistant to the campaign manager for Georgia Governor Zell Miller's high-profile re-election effort in 1994, and worked for a public affairs firm based in Austin, Texas, Public Strategies.

Her previous experience at Public Strategies coupled with her work in the Georgia state legislature and on Zell Miller's high profile gubernatorial election bid in 1994, created a platform for success in leading teams, corporations and clients to the successful pursuit and realization of their key priorities.

Samantha has a distinguished track record as a life science sector investor, asset manager, entrepreneur and scientist. She is founder of Surrey Capital Partners, a life science impact innovation fund. At the request of MD Anderson, Surrey Capital Partners has been asked to create a fund in collaboration with MD Anderson. Surrey Capital Moonshot Fund with MD Anderson will be focused on Parkinson, Cancer, Alzheimer’s Disease and areas of the brain affected by Cancer. MD Anderson is shifting the paradigm on how we are looking at Neurodegeneration and Cancer with a multidisciplinary approach.

Samantha is Co-Founder and Managing Partner, Decision Medical Ventures, a New York and California-based life sciences investment firm. She currently sits on the board of Decision Sciences Medical Company, an affiliate of Decision Sciences focused on bringing to market an advanced medical ultrasound technology for the early, noninvasive detection of cancer and other serious medical conditions.

Samantha’s experience includes working for a large pharmaceutical company in World Wide Business Development, R&D, and Mergers and Acquisitions. She has managed and closed investments in the pharmaceutical, biotechnology, medical device and diagnostics areas. Samantha has 12 years of experience working in the life sciences/pharmaceutical industry in the areas of Private Equity Venture Capital, as well as business development for a major pharmaceutical company. She was responsible for managing a portfolio of investments and negotiating global deals in licensing, collaborations, and acquisitions with other pharmaceutical and biotech companies, fund of fund investments, and financial valuations.

Samantha previously worked at a venture capital private equity fund in London, focusing on life sciences in areas of biotechnology, medical devices, therapeutics, and nanotechnology. She also held positions at the Cabinet Office in the Ministry of Science and Technology working on the Global Innovation Forum.

Samantha graduated summa cum laude with an M.S. Eng. and a M.B. in biomedical engineering and biotechnology, respectively, from University of Pennsylvania, with a joint published thesis from the Library of Congress in robotic surgery with the Engineering School at Oxford University. Samantha holds an undergraduate degree in Engineering and Applied Mathematics from Cornell University. She has recently been asked to join the University of Pennsylvania School for Engineering and Medicine as a faculty advisory board member.

She has a published paper that was presented at the Engineering and Medicine Society Conference in France with the Jet Propulsion Laboratory and NASA, as well a published thesis on Artificial Muscles and the Applications to Robotic Surgery. Samantha holds numerous publications as well as a patent in 3-D protein modeling sold to Microsoft for genomics. She has an Executive Finance Degree from Wharton and completed the Private Equity Venture Capital Program at Harvard Business School. She is currently in the Owner’s President Management Program at Harvard Business School. She was nominated for the “Rising Star” award in Science, Women, and Engineering in 2010.